Robert J. Kreitman

17.1k total citations · 2 hit papers
243 papers, 12.4k citations indexed

About

Robert J. Kreitman is a scholar working on Immunology, Biotechnology and Genetics. According to data from OpenAlex, Robert J. Kreitman has authored 243 papers receiving a total of 12.4k indexed citations (citations by other indexed papers that have themselves been cited), including 186 papers in Immunology, 97 papers in Biotechnology and 82 papers in Genetics. Recurrent topics in Robert J. Kreitman's work include Toxin Mechanisms and Immunotoxins (155 papers), Transgenic Plants and Applications (92 papers) and Chronic Lymphocytic Leukemia Research (82 papers). Robert J. Kreitman is often cited by papers focused on Toxin Mechanisms and Immunotoxins (155 papers), Transgenic Plants and Applications (92 papers) and Chronic Lymphocytic Leukemia Research (82 papers). Robert J. Kreitman collaborates with scholars based in United States, United Kingdom and Germany. Robert J. Kreitman's co-authors include Ira Pastan, Raffit Hassan, David J. FitzGerald, Maryalice Stetler‐Stevenson, Wyndham H. Wilson, Raj K. Puri, Masanori Onda, Evgeny Arons, David Fitzgerald and Mark C. Willingham and has published in prestigious journals such as Science, New England Journal of Medicine and Cell.

In The Last Decade

Robert J. Kreitman

240 papers receiving 12.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

2017 607 citations Vivek Subbiah, Robert J. Kreitman et al. Journal of Clinical Oncology profile →
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

2022 183 citations Vivek Subbiah, Robert J. Kreitman et al. profile →

Peers

Countries citing papers authored by Robert J. Kreitman

Since Specialization

Citations

This map shows the geographic impact of Robert J. Kreitman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert J. Kreitman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert J. Kreitman more than expected).

Fields of papers citing papers by Robert J. Kreitman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert J. Kreitman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert J. Kreitman. The network helps show where Robert J. Kreitman may publish in the future.

Co-authorship network of co-authors of Robert J. Kreitman

This figure shows the co-authorship network connecting the top 25 collaborators of Robert J. Kreitman. A scholar is included among the top collaborators of Robert J. Kreitman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert J. Kreitman. Robert J. Kreitman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia 2025 ·Blood ·Brett Schroeder, Constance M. Yuan, Hao‐Wei Wang, (unknown), Hong Zhou, Mark Raffeld, Liqiang Xi, Evgeny Arons, (unknown), (unknown), Katherine R. Calvo, Irina Marić, Robert J. Kreitman	0
2	COVID-19 in patients with classic and variant hairy cell leukemia 2023 ·Blood Advances ·Robert J. Kreitman, (unknown), (unknown), (unknown), (unknown), (unknown), M N Gould, (unknown), Hong Zhou, Peter D. Burbelo, Jeffrey I. Cohen, Hao‐Wei Wang, Constance M. Yuan, Evgeny Arons	2
3	Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer breakdown → 2017 ·Journal of Clinical Oncology ·Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Y. Choi, Jan H.M. Schellens, Jean Charles Soria, Patrick Y. Wen, Christoph Zielinski, Maria E. Cabanillas, Gladys Urbanowitz, Bijoyesh Mookerjee, (unknown), Fatima Rangwala, Bhumsuk Keam	607
4	Effect of Antigen Shedding on Targeted Delivery of Immunotoxins in Solid Tumors from a Mathematical Model 2014 ·PLoS ONE ·Youngshang Pak, Ira Pastan, Robert J. Kreitman, Byung Kook Lee	15
5	Distinguishing hairy cell leukemia variant from hairy cell leukemia: Development and validation of diagnostic criteria 2013 ·Leukemia Research ·Haipeng Shao, Katherine R. Calvo, (unknown), Prashant Tembhare, Robert J. Kreitman, Maryalice Stetler‐Stevenson, Constance M. Yuan	81
6	Adhesion of Hairy Cells Leukemia (HCL) Cells to Stromal Cells Can Be Inhibited by Blocking VLA-4 Integrins and CXCR4 Chemokine Receptors 2011 ·Blood ·Mariela Sivina, Robert J. Kreitman, Amnon Peled, Farhad Ravandi, Jan A. Burger	10
7	The improvement of an anti-CD22 immunotoxin 2011 ·mAbs ·(unknown), Masanori Onda, Mitchell Ho, Robert J. Kreitman, Tapan K. Bera, Ira Pastan	12
8	Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo 2007 ·The Journal of Immunology ·Daniel J. Powell, Aloísio Felipe-Silva, Maria J. Merino, Mojgan Ahmadzadeh, (unknown), Catherine Lévy, Donald E. White, Sharon Mavroukakis, Robert J. Kreitman, Steven A. Rosenberg, Ira Pastan	139
9	Characterization of CAT-8015: A Pseudomonas exotoxin based immunotoxin for the treatment of CD22-related hematological malignancies 2006 ·Cancer Research ·Ralph Alderson, Enrique Escandón, Tianling Chen, (unknown), (unknown), Wei Geng, David Fitzgerald, Robert J. Kreitman, Ira Pastan, (unknown)	13
10	Characterization of the B Cell Epitopes Associated with a Truncated Form of Pseudomonas Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients 2006 ·The Journal of Immunology ·Masanori Onda, Satoshi Nagata, David Fitzgerald, Richard Beers, Robert J. Fisher, James J. Vincent, Byung Kook Lee, Michihiro Nakamura, Jaulang Hwang, Robert J. Kreitman, Raffit Hassan, Ira Pastan	92
11	Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy 2005 ·Cancer Immunology Immunotherapy ·Evgeny Arons, Lynn Sorbara, Mark Raffeld, Maryalice Stetler‐Stevenson, Seth M. Steinberg, David J. Liewehr, Ira Pastan, Robert J. Kreitman	11
12	Localization of Mesothelin in Epithelial Ovarian Cancer 2005 ·Applied immunohistochemistry & molecular morphology ·Raffit Hassan, Robert J. Kreitman, Ira Pastan, Mark C. Willingham	147
13	Recombinant immunotoxins for the treatment of haematological malignancies 2004 ·Expert Opinion on Biological Therapy ·Robert J. Kreitman	16
14	Multidrug-resistant tumor cells remain sensitive to a recombinant interleukin-4-Pseudomonas exotoxin, except when overexpressing the multidrug resistance protein MRP1. 2003 ·PubMed ·Mariska C. de Jong, George L. Scheffer, Henk J. Broxterman, Jan Hendrik Hooijberg, Jerry W. Slootstra, Rob H. Meloen, Robert J. Kreitman, Syed R. Husain, Bharat Joshi, Raj K. Puri, Rik J. Scheper	8
15	Making Fusion Toxins to Target Leukemia and Lymphoma 2003 ·Humana Press eBooks ·Robert J. Kreitman, Ira Pastan	6
16	Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncatedpseudomonas exotoxin 2001 ·International Journal of Cancer ·(unknown), Partha S. Chowdhury, Ira Pastan, Robert J. Kreitman	18
17	Inhibition of TNF-α Produced by Kupffer Cells Protects Against the Nonspecific Liver Toxicity of Immunotoxin Anti-Tac(Fv)-PE38, LMB-2 2000 ·The Journal of Immunology ·Masanori Onda, Mark C. Willingham, Qingcheng Wang, Robert J. Kreitman, Yasuo Tsutsumi, Satoshi Nagata, Ira Pastan	53
18	Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys 1999 ·International Journal of Cancer ·Robert J. Kreitman, Qingcheng Wang, David Fitzgerald, Ira Pastan	78
19	Rapid and specific uptake of anti-Tac disulfide-stabilized Fv by interleukin-2 receptor-bearing tumors. 1995 ·PubMed ·Keith O. Webber, Robert J. Kreitman, I Pastan	15
20	The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans 1994 ·Journal of Cell Science ·Enrique A. Mesri, Minoru Ōno, Robert J. Kreitman, Michael Klagsbrun, Ira Pastan	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact